Restricting use of adenovirus vector-based COVID vaccines could endanger public and global health

Hildegund C J Ertl; Sue L Currie; Andrew D Luber

doi:10.3389/fimmu.2022.985382

Restricting use of adenovirus vector-based COVID vaccines could endanger public and global health

Front Immunol. 2022 Aug 25:13:985382. doi: 10.3389/fimmu.2022.985382. eCollection 2022.

Authors

Hildegund C J Ertl¹, Sue L Currie², Andrew D Luber²

Affiliations

¹ The Wistar Institute, Philadelphia, PA, United States.
² Virion Therapeutics, LLC, Newark, DE, United States.

No abstract available

Keywords: COVID; VITT; adenoviral (Ad) vector; benefit-risk strategies; global public health; myocarditis; thrombosis with thrombocytopenia syndrome (TTS); vaccines.

MeSH terms

Adenoviridae / genetics
Adenovirus Vaccines*
COVID-19 Vaccines
COVID-19* / prevention & control
Global Health
Humans
Vaccines*

Substances

Adenovirus Vaccines
COVID-19 Vaccines
Vaccines